Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to...
- How to Source Non-IMP Supplies for Clinical Trials
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- How Whole Systems Thinking Could Transform the Clinical Supply Chain
- Integrating New Assets: A Supply Chain Perspective
- The Dawn of Cell Therapies, Blockchain, and M&A: Industry Trends in the CMO Landscape
IoT Tracking and Monitoring
Cell and gene therapy shipments involve a complex sequence of events with precise planning and coordination of the stakeholders involved. The medicines are unique and have vulnerable characteristics.
Catalent launches new clinical trial planning service
US-based Catalent has unveiled a new solution to support trial sponsors with clinical supply chain planning.
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
Marken unveils protective thermal box to ship clinical drug products
Marken, a clinical supply chain subsidiary of UPS, has launched a new custom-designed and protective thermal box for shipment of clinical drug products.
The Perfect Remedy for Clinical Trial Distribution
Over the past decade, the distribution of Investigational Medicinal Products (IMPs) has become a complex part of the supply chain for companies involved in new drug development.
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.